55,000 Shares CTI BioPharma Corp. Series N-2 Preferred Stock UNDERWRITING AGREEMENTUnderwriting Agreement • December 9th, 2015 • Cti Biopharma Corp • Pharmaceutical preparations • New York
Introductory. CTI BioPharma Corp., a Washington corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 55,000 shares of its Series N-2 Preferred Stock, no par value per share (the “Offered Shares”). Piper Jaffray & Co. (“Piper Jaffray”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representative” as used herein shall mean you, as Underwriter, and the term “Underwriters” shall mean either the singular or the plural, as the context requires.
December 9, 2015 BVF Partners L.P. One Sansome Street, 39th Floor San Francisco, CA 94104 Ladies and Gentlemen:Board Nomination Rights Agreement • December 9th, 2015 • Cti Biopharma Corp • Pharmaceutical preparations • New York
In exchange for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each of CTI BioPharma Corp., a Washington corporation (the “Company”), and BVF Partners L.P. (“BVF” and, together with its affiliates, the “Shareholder”) agree as follows:
